MercachemSyncom acquires the European operations of Alcami - Gilde Healthcare

MercachemSyncom acquires the European operations of Alcami

January 9, 2020

Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, has announced that it has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands.

The acquisition will allow MercachemSyncom to support larger scale clinical active pharmaceutical ingredient (API) requirements, as well as bringing state-of-the-art solid-state research capabilities. The long experience of the Weert team in designing and driving early clinical drug substance development programs will complement extensive medicinal chemistry and process research capabilities based in Groningen and Nijmegen. The business combination approaches EUR 60M in revenues.

The Weert facility, originally founded in 1999 as Chemshop B.V., has steadily developed into a state-of-the-art contract development and manufacturing organization (CDMO), with a highly skilled workforce focused on applying appropriate development to transition laboratory-scale chemistry to cGMP clinical drug substance production.

Eelco Ebbers, CEO, commented,

“This acquisition, allows us to offer a portfolio of services from compound design to clinical proof of concept and beyond, all located within the European Union. We are extremely happy to acquire these operations, particularly as they come with such an experienced team. This is our second acquisition in the cGMP space, following our Prague site. We are excited about the additional capacity and capability we will be able to offer. The Weert site has a proven track record and state-of-the-art facilities.”

Rafael Natanek, Partner at Gilde Healthcare, commented,

“This acquisition is part of the active buy-and-build strategy we are pursuing together with Management. It solidifies MercachemSyncom as the premier mid-sized CRO in Europe with an integrated contract research service offering from hit-finding to Phase 2a”.

Debt financing in support of the transaction was provided by Crescent Capital Group LP.

 

About MercachemSyncom
MercachemSyncom is the leading mid-sized European contract research organization offering innovative chemistry, medicinal chemistry, early drug substance development, and GMP production services to accelerate the drug discovery and development process in a flexible and cost-effective way. MercachemSyncom offers integrated drug-discovery services from hit to clinic. Working for many pharmaceutical and biotech companies throughout the world, MercachemSyncom is recognized for its high-quality products and services and its unprecedented problem-solving capabilities. For more information, visit the company’s website at www.mercachemsyncom.com.

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing € 1 billion ($ 1.2 billion) across two fund strategies: private equity and venture & growth capital. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022